Biopharmaceutical
Technology
Pharmaceutical

Achaogen

$0.54
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.0245 (4.71%) Today
-$0.0049 (-0.90%) After Hours

Why Robinhood?

You can buy or sell Achaogen and other stocks, options, ETFs, and crypto commission-free!

About

Achaogen, Inc. Common Stock, also called Achaogen, is a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections. Read More It offers Plazomicin to treat bacterial illness, such as complicated urinary tract infection, blood stream infections, and other infections due to MDR Enterobacteriaceae. The company was founded by Nathaniel E. David in June 2002 and is headquartered in South San Francisco, CA.

Employees
230
Headquarters
South San Francisco, California
Founded
2002
Market Cap
23.92M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.21M
High Today
$0.551
Low Today
$0.52
Open Price
$0.55
Volume
531.78K
52 Week High
$15.00
52 Week Low
$0.51

Collections

Biopharmaceutical
Technology
Pharmaceutical
Health
Research And Development
2014 IPO

News

Simply Wall StMar 6

What You Must Know About Achaogen, Inc.’s (NASDAQ:AKAO) Beta Value

Anyone researching Achaogen, Inc. (NASDAQ:AKAO) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility as falling into two main categories. The first category is company specific volatility. This can be dealt with by limiting your exposure to any particular stock. The second type is the broader market volatility, which you cannot diversify away, since it arises from macroeconomic factor...

417
MarketBeatMar 2

Stock Price, News, & Analysis for Achaogen

Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved i...

225
Seeking AlphaFeb 22

Achaogen's Last Capital Raise Signals Desperation

With time and money running out, Achaogen has nearly no leverage for a potential M&A move to get itself acquired - any potential buyer can afford to wait Achaogen out for a better deal.

957

Earnings

-$1.20
-$1.01
-$0.81
-$0.62
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.75 per share
Actual
Available Mar 28, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.